TACROLIMUS FOR ECZEMA

Statement Regarding FDA Decision On Two Eczema Medications By American Academy Of DermatologyThe American Academy of Dermatology (Academy) today issued a statement in response to the U.S. Food and Drug Administration's (FDA) announcement that it is adding a black box warning to the health professional label for pimecrolimus and tacrolimus in addition to developing a medication guide for patients. "The American Academy of Dermatology is disappointed that the FDA has taken this action, despite the fact that there is no data that proves proper topical use of pimecrolimus and tacrolimus is dangerous in people," said dermatologist Clay J. Cockerell, M.D., president of the American Academy of Dermatology. "Because these medications are applied to the skin, virtually none of it gets inside the body. It's not the same as taking a pill. These are valuable medications, and if used properly, they significantly reduce the debilitating impact of eczema and allow millions of our patients to live normal lives.